Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryJul 24, 2014	Xencor to Host Second Quarter 2014 Financial Results Webcast and Conference Call MONROVIA, Calif. , July 24, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release second quarter	View HTML Xencor to Host Second Quarter 2014 Financial Results Webcast and Conference Call 12.7 KB
Toggle SummaryJul 28, 2015	Xencor to Host Second Quarter 2015 Financial Results Webcast and Conference Call on August 4, 2015 MONROVIA, Calif. , July 28, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release second quarter 2015	View HTML Xencor to Host Second Quarter 2015 Financial Results Webcast and Conference Call on August 4, 2015 15.9 KB
Toggle SummaryJul 26, 2016	Xencor to Host Second Quarter 2016 Financial Results Webcast and Conference Call on August 2, 2016 MONROVIA, Calif. , July 26, 2016 /PRNewswire/ -- Xencor , Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release second quarter	View HTML Xencor to Host Second Quarter 2016 Financial Results Webcast and Conference Call on August 2, 2016 14.1 KB
Toggle SummaryJul 31, 2017	Xencor to Host Second Quarter 2017 Financial Results Webcast and Conference Call on August 7, 2017 MONROVIA, Calif. , July 31, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release second quarter	View HTML Xencor to Host Second Quarter 2017 Financial Results Webcast and Conference Call on August 7, 2017 30.8 KB
Toggle SummaryJul 30, 2018	Xencor to Host Second Quarter 2018 Financial Results Webcast and Conference Call on August 6, 2018 MONROVIA, Calif. , July 30, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release second quarter	View HTML PDF Version
Toggle SummaryJul 30, 2019	Xencor to Host Second Quarter 2019 Financial Results Webcast and Conference Call on August 6, 2019 MONROVIA, Calif. --(BUSINESS WIRE)--Jul. 30, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that it will release second quarter	View HTML PDF Version
Toggle SummaryJul 28, 2020	Xencor to Host Second Quarter 2020 Financial Results Webcast and Conference Call on August 4, 2020 MONROVIA, Calif. --(BUSINESS WIRE)--Jul. 28, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will release second quarter 2020 financial results	View HTML PDF Version
Toggle SummaryJul 28, 2021	Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021 MONROVIA, Calif. --(BUSINESS WIRE)--Jul. 28, 2021-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release second quarter 2021	View HTML PDF Version
Toggle SummaryJul 27, 2022	Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022 MONROVIA, Calif. --(BUSINESS WIRE)--Jul. 27, 2022-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release second quarter 2022 financial results after	View HTML PDF Version
Toggle SummaryJul 27, 2023	Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023 PASADENA, Calif. --(BUSINESS WIRE)--Jul. 27, 2023-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release second quarter 2023 financial results after	View HTML PDF Version

Tools

Press Releases